<h4>Introduction</h4>Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) or aromatase inhibitor-induced arthralgia (AIA), common side effects of long-term adjuvant endocrine therapy for breast cancer patients, can significantly affect quality of life. Here, CYP19A1 is linked to breast cancer.